Although proton pump inhibitors are a mainstay in preventing cancer in patients with Barrett’s esophagus, 56% of these patients fall off PPI adherence during the year following BE diagnosis, a new analysis has revealed.
The study also found predictors of poor adherence, including new use of PPIs, male sex and specific comorbidities.
“Our findings have implications for BE care management,” noted the researchers, who were led by Charles Gaber, MPH, PhD, an assistant professor in